One Impact of the COVID-19 Pandemic on the Pediatric Population: MIS-C

In late April 2020, healthcare providers in the United Kingdom and the United States began to recognize a severe inflammatory syndrome in the pediatric population; otherwise-healthy children were presenting with signs of inflammation comparable to Kawasaki disease. In May, the CDC provided a case definition, referring to this novel presentation in pediatric patients as multisystem inflammatory syndrome in children. A small number of studies have been published, providing limited data on presentation and outcomes. There are no definitive guidelines for treatment, but IV immunoglobulin and supportive care are common approaches.